Acolab Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 12-07-2024
- Paid Up Capital ₹ 0.10 M
as on 12-07-2024
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 25.52%
(FY 2017)
- Profit 660.75%
(FY 2017)
- Ebitda 106.28%
(FY 2017)
- Net Worth 40.45%
(FY 2017)
- Total Assets 79.19%
(FY 2017)
About Acolab Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Lalit Goswami and Deepu Puri serve as directors at the Company.
- CIN/LLPIN
U24100GJ2015PTC082879
- Company No.
082879
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Acolab Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lalit Goswami  | Director | 13-Apr-2015 | Current |
| Deepu Puri | Director | 13-Apr-2015 | Current |
Financial Performance of Acolab Pharmaceuticals.
Acolab Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 25.52% increase. The company also saw a substantial improvement in profitability, with a 660.75% increase in profit. The company's net worth Soared by an impressive increase of 40.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Acolab Pharmaceuticals?
In 2017, Acolab Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Acolab Pharmaceuticals?
Unlock and access historical data on people associated with Acolab Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Acolab Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Acolab Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
